{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "therapeutic-intervention", "type": "definition", "offset": [177, 201]}, {"key": "not-limited", "type": "clause", "offset": [231, 242]}, {"key": "protein-expression", "type": "definition", "offset": [265, 283]}], "size": 21, "snippet": "means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. Biomarkers include, but are not limited to, gene mutations or protein expression.", "samples": [{"hash": "bxrC8ISa9lO", "uri": "https://go.gallagherstudent.com/-/media/files/gsh/universities/5105/plan-year-24-25/20242025-tulane-university-tship-certificate-of-coverage-for-distance-learning-students.pdf", "label": "go.gallagherstudent.com", "score": 19.3724504488, "published": false}, {"hash": "hEGzxLTFmle", "uri": "https://go.gallagherstudent.com/-/media/files/gsh/universities/5110/scd-5714/20242025-xavier-university-ship-certificate-of-coverage.pdf", "label": "go.gallagherstudent.com", "score": 19.3665733337, "published": false}, {"hash": "lChhTjpFYFx", "uri": "https://go.gallagherstudent.com/-/media/files/gsh/universities/5153/scd-5622/20242025-lsu--hsc-shreveport-student-health-insurance-certificate-of-insurance.pdf", "label": "go.gallagherstudent.com", "score": 19.1812324524, "published": false}], "hash": "4c6589c43d3bd3ddadd86d317d410ed5", "id": 1}, {"snippet_links": [{"key": "patient-sample", "type": "definition", "offset": [52, 66]}, {"key": "measurement-of", "type": "clause", "offset": [72, 86]}, {"key": "for-purposes-of", "type": "clause", "offset": [107, 122]}, {"key": "treatment-of", "type": "clause", "offset": [330, 342]}], "size": 15, "snippet": "means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.", "samples": [{"hash": "1kLIEO7BX4G", "uri": "/contracts/1kLIEO7BX4G#biomarker", "label": "Global License Agreement (Prothena Corp Public LTD Co)", "score": 35.6009597778, "published": true}, {"hash": "e9TFvuw6o6f", "uri": "/contracts/e9TFvuw6o6f#biomarker", "label": "Global License Agreement (Prothena Corp Public LTD Co)", "score": 34.8343582153, "published": true}, {"hash": "2ygNhRQXI3J", "uri": "/contracts/2ygNhRQXI3J#biomarker", "label": "u.s. License Agreement (Prothena Corp Public LTD Co)", "score": 32.8412055969, "published": true}], "hash": "03314fe3802c9209dc8e0e0dcaeb0942", "id": 2}, {"snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [77, 95]}, {"key": "therapeutic-intervention", "type": "definition", "offset": [245, 269]}], "size": 13, "snippet": "means a distinctive biological or biologically derived indicator (including, without limitation, DNA, RNA, protein, peptide, antibodies and cells) by which particular normal biologic processes, pathogenic processes or pharmacologic responses to therapeutic intervention can be identified, quantified or predicted.", "samples": [{"hash": "bFHl6qr07eF", "uri": "/contracts/bFHl6qr07eF#biomarker", "label": "Research and Development Collaboration and License Agreement (Compugen LTD)", "score": 33.1587944031, "published": true}, {"hash": "4fvmsERBTP6", "uri": "/contracts/4fvmsERBTP6#biomarker", "label": "Research and Development Collaboration and License Agreement (Compugen LTD)", "score": 32.1512680054, "published": true}, {"hash": "68ylWgeDbnz", "uri": "/contracts/68ylWgeDbnz#biomarker", "label": "Research and Development Collaboration and License Agreement (Compugen LTD)", "score": 25.6488704681, "published": true}], "hash": "1e1ad1d3068395bf437663a227bb353a", "id": 3}, {"snippet_links": [{"key": "administration-of", "type": "clause", "offset": [64, 81]}, {"key": "not-limited", "type": "clause", "offset": [103, 114]}, {"key": "is-likely", "type": "definition", "offset": [159, 168]}, {"key": "therapeutic-agent", "type": "definition", "offset": [226, 243]}, {"key": "clinical-practice", "type": "definition", "offset": [276, 293]}], "size": 9, "snippet": "means a biological marker that can be used to guide therapeutic administration of a drug including but not limited to: (i) to predict whether or not a patient is likely to be sensitive or resistant to treatment with a certain therapeutic agent; or (ii) to guide any aspect of clinical practice (e.g. dosing, safety, efficacy and response).", "samples": [{"hash": "9MOeFniwOyj", "uri": "/contracts/9MOeFniwOyj#biomarker", "label": "Cooperative Research and Development Agreement", "score": 31.3408622742, "published": true}, {"hash": "hade2X1o2Yd", "uri": "/contracts/hade2X1o2Yd#biomarker", "label": "Cooperative Research and Development Agreement", "score": 29.1600933075, "published": true}, {"hash": "7yWiVzlVBjY", "uri": "/contracts/7yWiVzlVBjY#biomarker", "label": "Cooperative Research and Development Agreement (Tracon Pharmaceuticals, Inc.)", "score": 25.9911022186, "published": true}], "hash": "2068bcd12fc07fb119edbf8dab657346", "id": 4}, {"snippet_links": [], "size": 8, "snippet": "means a defined characteristic that is", "samples": [{"hash": "1PInnjRkae", "uri": "https://flsenate.gov/Session/Bill/2024/964/Amendment/237278/PDF", "label": "flsenate.gov", "score": 16.8052349091, "published": false}, {"hash": "7kJbmc8mGjX", "uri": "https://www.flsenate.gov/Session/Bill/2025/975/BillText/Filed/PDF", "label": "www.flsenate.gov", "score": 15.9934606552, "published": false}, {"hash": "8YGbgyVpsVA", "uri": "https://m.flsenate.gov/session/bill/2024/964/billtext/c2/pdf", "label": "m.flsenate.gov", "score": 11.0609169006, "published": false}], "hash": "53ff195083840567ae3cf0fad233d934", "id": 5}, {"snippet_links": [], "size": 8, "snippet": "means a characteristic that is objectively measured and", "samples": [{"hash": "465NgFsFMKA", "uri": "https://www.benefits-partners.com/media/woyijcah/la_sb_104_act_324.pdf", "label": "www.benefits-partners.com", "score": 16.0332374573, "published": false}, {"hash": "dS2O0MojBLO", "uri": "https://www.legis.la.gov/Legis/ViewDocument.aspx?d=1308205", "label": "www.legis.la.gov", "score": 16.0287666321, "published": false}, {"hash": "2R612FPxKGB", "uri": "https://legis.la.gov/legis/ViewDocument.aspx?d=1313063", "label": "legis.la.gov", "score": 15.9395160675, "published": false}], "hash": "595c009b43cade4614870d6c494605a6", "id": 6}, {"snippet_links": [], "size": 8, "snippet": "means a characteristic that is objectively measured and evaluated as an", "samples": [{"hash": "4FiJXuN99zS", "uri": "http://webserver.rilin.state.ri.us/BillText/BillText22/SenateText22/S2201A.pdf", "label": "webserver.rilin.state.ri.us", "score": 11.2286109924, "published": false}, {"hash": "hXYKvuxqSgn", "uri": "http://webserver.rilin.state.ri.us/BillText/BillText22/HouseText22/H7587A.pdf", "label": "webserver.rilin.state.ri.us", "score": 11.2286109924, "published": false}, {"hash": "lNJMcGC7KAo", "uri": "https://webserver.rilegislature.gov/BillText22/HouseText22/H7587.pdf", "label": "webserver.rilegislature.gov", "score": 11.072552681, "published": false}], "hash": "442ded496b3b7275fe94ec545f71ec8c", "id": 7}, {"snippet_links": [{"key": "therapeutic-intervention", "type": "definition", "offset": [186, 210]}], "size": 8, "snippet": "means an endogenous characteristic that is objectively measured and evaluated as an indicator or predictor of normal biological or pathogenic processes or pharmacological responses to a therapeutic intervention.", "samples": [{"hash": "9PnLzp6dzA6", "uri": "/contracts/9PnLzp6dzA6#biomarker", "label": "Licence Agreement", "score": 31.3408622742, "published": true}, {"hash": "Q4T6r5PCFr", "uri": "/contracts/Q4T6r5PCFr#biomarker", "label": "Licence Agreement (Nuvectis Pharma, Inc.)", "score": 30.8028755188, "published": true}, {"hash": "hZ7ahc5xHG8", "uri": "/contracts/hZ7ahc5xHG8#biomarker", "label": "Licence Agreement (Nuvectis Pharma, Inc.)", "score": 30.761806488, "published": true}], "hash": "b71ca89d150dc96cc3cdc3c47ccc13e8", "id": 8}, {"snippet_links": [{"key": "patient-sample", "type": "definition", "offset": [52, 66]}, {"key": "measurement-of", "type": "clause", "offset": [72, 86]}, {"key": "for-purposes-of", "type": "clause", "offset": [107, 122]}, {"key": "treatment-of", "type": "clause", "offset": [273, 285]}], "size": 8, "snippet": "means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.", "samples": [{"hash": "dfyoyY81UyK", "uri": "/contracts/dfyoyY81UyK#biomarker", "label": "Exclusive License and Collaboration Agreement (BeiGene, Ltd.)", "score": 28.8658447266, "published": true}, {"hash": "21jqhJHwbSo", "uri": "/contracts/21jqhJHwbSo#biomarker", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.9952087402, "published": true}, {"hash": "bWfZFtNszMb", "uri": "/contracts/bWfZFtNszMb#biomarker", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.77891922, "published": true}], "hash": "657a16ad8ed16f252d5e842b5dd10901", "id": 9}, {"snippet_links": [{"key": "therapeutic-intervention", "type": "definition", "offset": [177, 201]}, {"key": "drug-interactions", "type": "definition", "offset": [225, 242]}, {"key": "not-limited", "type": "clause", "offset": [338, 349]}, {"key": "characteristics-of", "type": "definition", "offset": [369, 387]}, {"key": "protein-expression", "type": "definition", "offset": [398, 416]}], "size": 6, "snippet": "means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene- drug interactions for medication being considered for use or currently administered. A biomarker includes but is not limited to gene mutations, characteristics of genes, or protein expression.", "samples": [{"hash": "bxrC8ISa9lO", "uri": "https://go.gallagherstudent.com/-/media/files/gsh/universities/5105/plan-year-24-25/20242025-tulane-university-tship-certificate-of-coverage-for-distance-learning-students.pdf", "label": "go.gallagherstudent.com", "score": 19.3724504488, "published": false}, {"hash": "hEGzxLTFmle", "uri": "https://go.gallagherstudent.com/-/media/files/gsh/universities/5110/scd-5714/20242025-xavier-university-ship-certificate-of-coverage.pdf", "label": "go.gallagherstudent.com", "score": 19.3665733337, "published": false}, {"hash": "lChhTjpFYFx", "uri": "https://go.gallagherstudent.com/-/media/files/gsh/universities/5153/scd-5622/20242025-lsu--hsc-shreveport-student-health-insurance-certificate-of-insurance.pdf", "label": "go.gallagherstudent.com", "score": 19.1812324524, "published": false}], "hash": "d96f75ed6a77abbdc7dbab4340b35843", "id": 10}], "next_curs": "ClYSUGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjILEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiISYmlvbWFya2VyIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 180, "snippet": "means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. Biomarkers include, but are not limited to, gene mutations or protein expression.", "title": "Biomarker", "id": "biomarker", "examples": ["<strong>Biomarker</strong> testing may be subject to cost sharing consistent with that imposed on testing benefits.", "<strong>Biomarker</strong> Testing for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring of a member\u2019s disease or condition is covered if the test is supported by medical and scientific evidence such as FDA approval, CMS national or local coverage determinations, or nationally recognized clinical practice guidelines.", "Current international initiatives to develop phantoms \u2022 Reference Image Database to Evaluate Response (RIDER) [1, 2] \u2022 Image Response Assessment Team (IRAT) \u2022 Quantitative Imaging Network (QIN) \u2022 AAPM: Working group for standards for quantitative MR measures \u2022 RSNA: Quantitative Imaging <strong>Biomarker</strong> Alliance (QIBA) [1].", "<strong>Biomarker</strong> testing is for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring of a member\u2019s disease or condition is covered if the test is supported by medical and scientific evidence such as FDA approval, CMS national or local coverage determinations, or nationally recognized clinical practice guidelines.", "Examples of Covered procedures include, but are not limited to, the following: Artery calcification testing (plan year 2022 and after) <strong>Biomarker</strong> Testing Computerized Axial Tomography (CAT) scans \u2013 requires Prior Authorization Magnetic Resonance Angiogram (MRA) tests, Magnetic Resonance Imaging (MRI) tests \u2013 requires Prior Authorization Sleep disorder studies in home or facility.", "At the request of bioM\u00e9rieux, Quanterix shall negotiate in good faith with bioM\u00e9rieux in an effort to reach commercially viable and reasonable terms and conditions for a worldwide license under any such <strong>Biomarker</strong> Intellectual Property Rights for use by bioM\u00e9rieux solely in connection with the Simoa Technology in the Exclusive Field.", "If Compugen or its Affiliate wishes to [***] (for the avoidance of doubt, on [***] basis) as a commercial product (for Compugen and/or for a licensee of Compugen) a Target <strong>Biomarker</strong> for [***] (e.g. [***]) than the one [***] (or if [***]), the procedure will be as follows: [***] of its interest [***], and shall [***] of such a product [***].", "Models of the Blood-Saliva Barrier Strengthens the Feasibility of Salivary cRp as <strong>Biomarker</strong> for Neonatal Sepsis.", "R-Pharm hereby assigns, and shall cause its Affiliates, and permitted sublicensees and its and their agent and subcontractors to assign, to OV the entire right, title and interest in and to all DRP <strong>Biomarker</strong> Agreement IP.", "R-Pharm shall not file any patent applications claiming, or amend any patent applications to claim, any DRP <strong>Biomarker</strong> Agreement IP."], "related": [["biomarker-testing", "Biomarker testing", "<strong>Biomarker</strong> testing"], ["bioassay", "Bioassay", "Bioassay"], ["assay", "Assay", "Assay"], ["antibody", "Antibody", "Antibody"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"]], "related_snippets": [], "updated": "2025-07-17T04:25:46+00:00"}, "json": true, "cursor": ""}}